http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3986428-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba3f70d4bcad1958ae8868ddab079b8f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001182
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
filingDate 2020-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0128ab928e30e3fa005fa3855cbfb83e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50d242e3e4c313b1314e3fe5d21ae43e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f6ca5a84970c235347db77e6b0fe3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_584daf19ce28dd79c81f4dc4a389e6ee
publicationDate 2022-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3986428-A1
titleOfInvention All-in one vector for car and therapeutic effector molecule
abstract The invention provides immune cells containing a nucleic acid construct, also referred to as a vector or viral vector, for use in immune therapy, e.g. for use in the treatment of cancer, or for use in the treatment of autoimmune disease, or for use in the treatment of GvH or HvG. The nucleic acid construct comprises a second expression cassette for constitutive expression of a CAR or a TCR, the binding of which to its target antigen results in signalling and induces the expression of an effector molecule from a first expression cassette, which is contained on the same nucleic acid construct, and which first expression cassette encodes the effector molecule under the control of a promoter inducible by signalling of the CAR or TCR.
priorityDate 2019-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397425
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398631

Total number of triples: 31.